منابع مشابه
Ponatinib: Accelerated Disapproval.
Drug development for life-threatening diseases is still a process in evolution. In oncology, as drugs have become more targeted, the regulatory path to drug approval has shortened, with increasing reliance on the Accelerated Approval pathway to provide early access to active agents. However, this approach is not without risks, as illustrated by the recent experience with ponatinib, a promising ...
متن کاملCutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib
Cutaneous lesions anticipating accelerated phase of multidrug resistant chronic myeloid leukemia responsive to ponatinib. permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. is the first tyrosine kinase inhibitor (TKI) to have potent and consistent activity against BCR-ABL1 with the T315I mutation. 1 The drug was developed based ...
متن کاملDisgust sensitivity predicts intuitive disapproval of gays.
Two studies demonstrate that a dispositional proneness to disgust ("disgust sensitivity") is associated with intuitive disapproval of gay people. Study 1 was based on previous research showing that people are more likely to describe a behavior as intentional when they see it as morally wrong (see Knobe, 2006, for a review). As predicted, the more disgust sensitive participants were, the more li...
متن کاملPonatinib in refractory Philadelphia chromosome-positive leukemias.
BACKGROUND Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) is frequently caused by mutations in the BCR-ABL kinase domain. Ponatinib (AP24534) is a potent oral tyrosine kinase inhibitor that blocks native and mutated BCR-ABL, including the gatekeeper mutant T315I, which i...
متن کاملPulmonary hypertension associated with ponatinib therapy.
Over 50 drugs, including anorexigens, abused substances and recently the tyrosine kinase inhibitor (TKI) dasatinib, have been temporally and/or mechanistically related to the development of pulmonary arterial hypertension (PAH) in humans (where the evidence base for causality is wide ranging) and in animal models [1–3]. The TKIs imatinib, dasatinib, nilotinib and bosutinib are available to trea...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Oncologist
سال: 2015
ISSN: 1083-7159,1549-490X
DOI: 10.1634/theoncologist.2015-0253